|
A selected list of oncolytic viruses in clinical trials
Click on the company or institution name for more information on the clinical trials
| Adenovirus |
E1B deletion restricts
replication to cells with abberant mRNA transport |
Head and neck tumors |
Phase III |
Sunway Biotech of China (H101) |
|
|
Head and neck tumors |
Phase III (canceled) |
Onyx (O15) |
| Coxsackie virus |
Targets DAF/intercellular
adhesion molecule 1, which is overexpressed in cancer |
Stage IV melanoma |
Phase I |
Viralytics (A21) |
| Herpes
simplex virus 1 |
ICP34.5 deletion restricts
replication to cells with active replication |
Melanoma |
Phase II |
BioVex (OncoVEXGM-CSF) |
|
|
Glioma, astrocytoma,
glioblastoma |
Phase I/II |
MediGene (G207, NV1020) |
|
|
Glioma, melanoma, squamous cell
carcinoma of the head and neck |
Phase I/II |
Crusade Laboratories (HSV1716) |
| Measles
virus |
Engineered to target CD46 on
tumor cells |
Brain and central nervous system
tumors |
Phase I |
Mayo Clinic (MV-CEA) |
| Newcastle
disease virus |
Naturally unable to replicate in
interferon-responsive cells |
Metastatic cancers |
Phase I |
Wellstat (PV701)
]; Hadassah Medical
Organization (MTH-68H) |
| Reovirus |
Naturally unable to infect cells
with active PKR |
Metastatic cancers, glioma |
Phase I/II |
Oncolytics (Reolysin) |
| Seneca
Valley Virus |
Naturally targets certain
tumor cells |
Solid tumors with neuroendocrine
features |
Phase I |
Neotropix (SVV-001) |
| Vaccinia |
Thymidine kinase deletion
prevents replication in cells with low nucleotide pool. |
Melanoma, Liver cancer |
Phase I/II |
Jennerex (JX-594) |
Advertisement
|
Register for FREE Online Access
Subscribe to the Magazine